Eliem Therapeutics Other Long-Term Assets 2021-2024 | CLYM
Eliem Therapeutics other long-term assets from 2021 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Eliem Therapeutics Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$3 |
Eliem Therapeutics Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$5 |
| 2022-03-31 |
$2 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
|
| 2021-06-30 |
$3 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
